Evidence map›Paper›PMID 35467014›Full record

ArticleClinical pharmacology and therapeutics2022

Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.

Martin Beliveau, Deborah Anderson, Doug Barker, Shantha Kodihalli, Emilie Simard, Christine Hall, Jason S Richardson

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02051062 (Pharmacokinetics of Botulism Antitoxin Heptavalent), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02051062 phase4enrolling by invitationnot on this map

Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin

TypeinterventionalSponsorEmergent BioSolutionsRan2014 to 2028Enrolled10ConditionsBotulismArmsBlood sample collection
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Martin BeliveauCertara Strategic Consulting, Montreal, Quebec, Canada.
Deborah AndersonEmergent BioSolutions Inc., Winnipeg, Manitoba, Canada.
Doug BarkerEmergent BioSolutions Inc., Winnipeg, Manitoba, Canada.
Shantha KodihalliEmergent BioSolutions Inc., Winnipeg, Manitoba, Canada.
Emilie SimardCertara Strategic Consulting, Montreal, Quebec, Canada.
Christine HallEmergent BioSolutions Inc., Winnipeg, Manitoba, Canada.
Jason S RichardsonEmergent BioSolutions Inc., Winnipeg, Manitoba, Canada.
Emergent BioSolutions (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulism antitoxin heptavalent (A, B, C, D, E, F, and G - Equine; BAT) product is a sterile solution of F(ab')

Indexed as

Botulinum AntitoxinBotulinum ToxinsBotulismAnimalsHorsesHumansBotulinum AntitoxinBotulinum Toxins

Identifiers

PMID35467014
PMCPMC9323444
OpenAlexW4224657289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.